• Profile
Close

A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: A first-in-humans study

The Journal of Infectious Diseases Apr 04, 2018

Langley JM, et al. - Researchers undertook a randomized, observer blinded first-in-humans study of a novel synthetic RSV antigen SHe, formulated with either the lipid and oil-based vaccine platform, DepoVax, termed DPX-RSV(A), or with alum, termed RSV(A) SHe, in healthy 50-64-year-old adults. The novel RSV antigen from the SH protein of RSV, formulated in a lipid and oil-based vaccine platform was observed to be highly immunogenic, with sustained antigen-specific antibody responses. they observed no safety signals. The most common solicited adverse events (AE) included mild pain, drowsiness and muscles aches which did not increase after dose 2. Very low responses to Alum-adjuvanted vaccines were noted.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay